TY - JOUR
T1 - Apolipoprotein A-IV inhibits experimental colitis
AU - Vowinkel, Thorsten
AU - Mori, Mikiji
AU - Krieglstein, Christian F.
AU - Russell, Janice
AU - Saijo, Fumito
AU - Bharwani, Sulaiman
AU - Turnage, Richard H.
AU - Davidson, W. Sean
AU - Tso, Patrick
AU - Granger, D. Neil
AU - Kalogeris, Theodore J.
PY - 2004/7
Y1 - 2004/7
N2 - The antiatherogenic properties of apoA-IV suggest that this protein may act as an anti-inflammatory agent. We examined this possibility in a mouse model of acute colitis. Mice consumed 3% dextran sulfate sodium (DSS) in their drinking water for 7 days, with or without daily intraperitoneal injections of recombinant human apoA-IV. apoA-IV significantly and specifically delayed the onset, and reduced the severity and extent of, DSS-induced inflammation, as assessed by clinical disease activity score, macroscopic appearance and histology of the colon, and tissue myeloperoxidase activity. Intravital fluorescence microscopy of colonic microvasculature revealed that apoA-IV significantly inhibited DSS-induced leukocyte and platelet adhesive interactions. Furthermore, apoA-IV dramatically reduced the upregulation of P-selectin on colonic endothelium during DSS-colitis. apoA-IV knockout mice exhibited a significantly greater inflammatory response to DSS than did their WT littermates; this greater susceptibility to DSS-induced inflammation was reversed upon exogenous administration of apoA-IV to knockout mice. These results provide the first direct support for the hypothesis that apoA-IV is an endogenous anti-inflammatory protein. This anti-inflammatory effect likely involves the inhibition of P-selectin-mediated leukocyte and platelet adhesive interactions.
AB - The antiatherogenic properties of apoA-IV suggest that this protein may act as an anti-inflammatory agent. We examined this possibility in a mouse model of acute colitis. Mice consumed 3% dextran sulfate sodium (DSS) in their drinking water for 7 days, with or without daily intraperitoneal injections of recombinant human apoA-IV. apoA-IV significantly and specifically delayed the onset, and reduced the severity and extent of, DSS-induced inflammation, as assessed by clinical disease activity score, macroscopic appearance and histology of the colon, and tissue myeloperoxidase activity. Intravital fluorescence microscopy of colonic microvasculature revealed that apoA-IV significantly inhibited DSS-induced leukocyte and platelet adhesive interactions. Furthermore, apoA-IV dramatically reduced the upregulation of P-selectin on colonic endothelium during DSS-colitis. apoA-IV knockout mice exhibited a significantly greater inflammatory response to DSS than did their WT littermates; this greater susceptibility to DSS-induced inflammation was reversed upon exogenous administration of apoA-IV to knockout mice. These results provide the first direct support for the hypothesis that apoA-IV is an endogenous anti-inflammatory protein. This anti-inflammatory effect likely involves the inhibition of P-selectin-mediated leukocyte and platelet adhesive interactions.
UR - http://www.scopus.com/inward/record.url?scp=4043165724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4043165724&partnerID=8YFLogxK
U2 - 10.1172/JCI200421233
DO - 10.1172/JCI200421233
M3 - Article
C2 - 15254593
AN - SCOPUS:4043165724
SN - 0021-9738
VL - 114
SP - 260
EP - 269
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -